Company Overview of N-of-One, Inc.
N-of-One, Inc., a molecular decision support company, provides clinicians with interpretation of molecular test results. It provides disease-specific biological relevance, clinical evidence, associated therapies, and references. The company also interprets next generation sequencing (NGS) of solid and hematological tumors, circulating tumor cells and DNA, copy number analysis, and immunohistochemistry. In addition, it offers PrecisionInsights, a clinical interpretation report for 15-20 gene NGS panels, delivering concise clinical and scientific evidence for each biomarker in the context of the cancer sub type and a list of therapeutic options; and TRIALMATCH, a patient-specific clinical tria...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One, Inc.
Chairman and Chief Executive Officer
Founder, President, Chief Medical Officer and Director
Chief Financial Officer and Director
Vice President of Operations
Vice President, Secretary and General Counsel
Compensation as of Fiscal Year 2016.
N-of-One, Inc. Key Developments
N-of-One, Inc. Presents at UBS Genomics 2.0 Summit, Aug-11-2016 11:00 AM
Aug 7 16
N-of-One, Inc. Presents at UBS Genomics 2.0 Summit, Aug-11-2016 11:00 AM. Venue: St. Regis Deer Valley, Park City, Utah, United States. Speakers: Christine M. Cournoyer, Chairman and Chief Executive Officer.
N-Of-One to Supply Admera Health with Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel
Apr 15 16
N-of-One reported that Admera Health has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne. N-of-One's patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient's molecular tests to therapeutic strategies, including clinical trials. N-of-One noted that the OncoGxOne is a next-generation sequencing panel that detects 64 of the most common mutated genes found in several cancer types. Mutation types detected include single nucleotide variants, insertions and deletions, copy number variants and gene fusions associated with all current FDA approved targeted therapies and multiple registered clinical trials.
Macrogen Selects N-of-One to Provide Patient-Specific Interpretation for the Launch of New Clinical Next-Generation Sequencing Panels
Apr 5 16
N-of-One, Inc. announced that Macrogen Corp. has selected N-of-One to provide high-quality clinical interpretation for its newly launched clinical next-generation sequencing (NGS) panels used for cancer patients. Financial terms of the agreement are not disclosed. N-of-One’s patient-specific analysis identifies therapeutic options based on each patient’s specific molecular profile identified by the sequencing data. These therapeutic options include therapies in guidelines, off label therapies, and the most relevant clinical trials prioritized based on molecular and geographical relevance.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 23, 2015